HEP-1
Also known as: Hepatocyte Peptide-1, Peptídeo Hepatocitário-1
Molecular Identifiers
Overview
Hepatocyte-derived peptide with hepatoprotective and regenerative properties. Designed to stimulate hepatocyte proliferation and support liver regeneration. In research phase as a potential therapeutic agent for chronic liver diseases and hepatocellular injury.
Interest around HEP-1 marketed as "Hepatocyte Peptide-1" centers on potential hepatoprotective effects and support for liver regeneration — hepatocyte proliferation, protection against oxidative stress, and modulation of repair pathways. This profile would be of interest in hepatic fibrosis, steatosis, and drug-induced hepatocellular injury.
HEP-1 currently has no regulatory approval from any agency (FDA, EMA, ANVISA) and is dispensed almost exclusively by compounding pharmacies as off-label use, in short cycles with subcutaneous administration and liver enzyme monitoring. Published scientific literature is very limited, and the chemical identity of the product marketed under this name has not been independently verified in public databases (PubMed, PubChem, UniProt, DrugBank) — see this record's notes for details.
Research peptide with limited published literature. Chemical identity not independently verified in public databases (PubMed, UniProt, DrugBank). Not to be confused with HEP-1 (Human Ezrin Peptide-1/Gepon), which is a distinct antiviral immunomodulator.
Half-life
~1-3 hours
Administration Route
Subcutaneous
Category
Specialized Research
Mechanism of Action
- Stimulation of hepatocyte proliferation via hepatic growth factors
- Support for liver regeneration after tissue injury
- Hepatocellular protection against oxidative stress
- Modulation of signaling pathways involved in liver repair
- Anti-apoptotic effect on damaged hepatocytes
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Mild abdominal discomfort
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 2 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of HEP-1 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 1-2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved — never shake
- Wait for complete dissolution before use
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 14 days)
- Protect from direct light
- Do not freeze after reconstitution
- Limited stability — prepare close to time of use
Scientific Studies
Published studies on HEP-1.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals